Aggressive Lymphomas
News
NCCN completes resource on radiation therapy
The National Comprehensive Cancer Network® (NCCN) has announced the release of the newly completed NCCN Radiation Therapy Compendium™. This...
News
Predicting neurotoxicity after CAR T-cell therapy
Researchers say they have identified potential biomarkers that may be used to help identify patients at an increased risk of neurotoxicity after...
News
Team identifies genetic drivers of DLBCL
Research published in Cell has revealed 150 genetic drivers of diffuse large B-cell lymphoma (DLBCL). Among these drivers are 27 genes newly...
From the Journals
Obinutuzumab edges out rituximab for PFS in follicular lymphoma
Three-year progression-free survival was 80% with obinutuzumab, vs. 73.3% with rituximab.
News
Newer blood cancer drugs may not improve OS, QOL
A study of cancer drugs approved by the European Commission from 2009 to 2013 showed that few hematology drugs were known to provide a benefit in...
News
Sperm banking may be underused by young cancer patients
New research suggests sperm banking may be underutilized by adolescent and young adult males with cancer who are at risk of infertility. However...
News
Drug receives breakthrough designation for HL
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to brentuximab vedotin (BV, Adcetris) for use in...
News
Doc advocates depression screening for cancer patients
SAN DIEGO—New research suggests a need for mental health screening among cancer patients. The study revealed a 40% rate of depression among...
Latest News
Adding bortezomib to R-CHOP didn’t improve survival in diffuse large B-cell lymphoma
Could the phase-2 PYRAMID trial’s bortezomib dosing explain the lack of significant benefit?
News
Maintenance will be a new standard in MCL, doc says
Results of a phase 3 trial suggest rituximab maintenance after transplant can prolong survival in non-elderly patients with mantle cell lymphoma (...
News
Representation in cancer clinical trials
ATLANTA—New research suggests some racial/ethnic minority groups are underrepresented in clinical trials for cancer patients in the US. African-...